Dermatol. praxi. 2021;15(2):74-76 [Pediatr. praxi. 2020;21(4):232-235]

Myths and pitfalls in management of patient with infantile hemangioma

MUDr. Josef Mališ, MUDr. Adéla Mišove
Klinika dětské hematologie a onkologie, 2. LF UK a FN Motol, Praha

Infantile hemangioma occurs in 5 to 10 % of children under one year of age. This benign vascular tumor is characterized by three phases of growth - proliferation, plateau, involution. Superficial hemangiomas reach their maximum size in 6 to 8 months, in deep ones rarely up to 2 years. Modern non-selective β-blocker therapy - propranolol - offers children an effective, safe and non-invasive solution. Starting the therapy in the proliferative phase is crucial for effectiveness.

Keywords: infantile hemangioma, propranolol.

Published: September 2, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mališ J, Mišove A. Myths and pitfalls in management of patient with infantile hemangioma. Dermatol. praxi. 2021;15(2):74-76.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kilcline C, Frieden IJ. Infantile Hemangiomas: How Common Are They? A Systematic Review of the Medical Literature; Pediatr. Dermatol. 2008; 25(2): 168-173. Go to original source... Go to PubMed...
    2. Léauté‑Labrèze C, Prey S, Ezzedine K. Infantile haemangioma: Part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities, J. Eur. Acad. Dermatology Venereol. 2011; (25)11: 1245-1253. Go to original source... Go to PubMed...
    3. Baselga E. et al. Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy.JAMA Dermatology 2016; 152(11): 1239-1243. Go to original source... Go to PubMed...
    4. Merrow AC, Gupta A, Patel MN, et al. 2014 Revised Classification of Vascular Lesions from the International Society for the Study of Vascular Anomalies: Radiologic‑Pathologic Update. RadioGraphics 2016; (36)5: 1494-1516. Go to original source... Go to PubMed...
    5. Vredenborg AD, Janmohamed SR, de Laat PCJ, et al.Multiple cutaneous infantile haemangiomas and the risk of internal haemangioma, Br. J. Dermatol., 2013; 169(1): 188-191. Go to original source... Go to PubMed...
    6. Léauté‑Labrèze C. et al. A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma, N. Engl. J. Med. 2015; 372(8): 735-746. Go to original source... Go to PubMed...
    7. Léauté‑Labrèze C, Roque ED, Hubiche T, et al. Propranolol for Severe Hemangiomas of Infancy, N. Engl. J. Med. 2008; 358(24): 2649-2651. Go to original source... Go to PubMed...
    8. Frommelt P, Juern A, Siegel D, et al. Adverse Events in Young and Preterm Infants Receiving Topical Timolol for Infantile Hemangioma. Pediatr Dermatol 2016; 33: 405-414. Go to original source... Go to PubMed...
    9. Shand DG. Pharmacokinetics of propranolol: a review. Postgraduate Medical Journal. 1976; 52(4): 22-25.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.